Sarcoidosis in the Eye: Symptoms, Diagnosis, and Treatment

Sarcoidosis affects the eyes in roughly one out of every four or five people who have the disease, making it one of the most common and potentially serious complications of the condition.¹ The inflammation can show up in nearly any structure of the eye, from the front surface to the optic nerve, and if left untreated it can cause permanent vision loss or blindness.² Because the signs often mimic other inflammatory conditions and sometimes appear before sarcoidosis is diagnosed elsewhere in the body, knowing what to watch for can make the difference between catching it early and losing vision you cannot get back.

How Sarcoidosis Affects Different Parts of the Eye

Sarcoidosis is a disease of tiny clusters of inflammatory cells called granulomas. In the eye, those granulomas and the immune-driven inflammation around them can settle into several distinct zones, each producing its own set of problems. The condition can involve the eye itself as well as surrounding tissues like the eyelids, tear glands, and the bony orbit.³

The most common presentation is uveitis, or inflammation of the middle layer of the eye wall. When it hits the front of the eye (anterior uveitis), it tends to cause redness, pain, light sensitivity, and blurred vision. A hallmark set of findings under the slit lamp includes large, greasy-looking clumps of inflammatory cells on the inner surface of the cornea, small nodules on the iris, and adhesions where the iris sticks to the lens.⁴ In adults, the disease is usually chronic and bilateral, meaning it tends to linger and affect both eyes.

When inflammation reaches the back of the eye (posterior uveitis or panuveitis), it can affect the retina, the choroid beneath it, and the vitreous gel that fills the eye. One characteristic finding is so-called “candle wax dripping” lesions along retinal blood vessels, where waxy-looking deposits form along the veins.⁵ Posterior involvement is especially concerning because it can cause swelling in the macula, the part of the retina responsible for sharp central vision.

Beyond the eyeball itself, sarcoidosis can enlarge the tear glands, causing a firm swelling near the outer upper eyelid, or inflame the optic nerve, leading to sudden or progressive loss of vision. Granulomas sometimes appear on the surface of the eye as small lumps on the conjunctiva, the clear membrane covering the white of the eye.³ Dry eyes are also common, since the disease can disrupt normal tear production.

Who Is Most Affected

Sarcoidosis itself does not affect every demographic equally, and those disparities carry over to its eye involvement. Research indicates that Black or African American patients with sarcoidosis develop anterior uveitis and optic nerve damage at higher rates than non-Hispanic white patients, while white patients more often develop inflammation in the back of the eye (chorioretinal inflammation). Interestingly, Black patients who initially present with eye inflammation are also more likely to be newly diagnosed with sarcoidosis in the months afterward, suggesting that for some people, eye symptoms are the first sign that anything is wrong.

Genetics appears to play a role in who develops eye involvement. A genome-wide analysis identified multiple genetic regions linked to ocular sarcoidosis, with some distinctions across ethnic groups. One gene region, HLA-DQB1, showed up consistently across African American, European, and East Asian populations and roughly doubled the odds of ocular sarcoidosis in each group.⁶ Distinct genetic susceptibility across ethnicities helps explain why the pattern of eye involvement varies by population, though environmental triggers and differences in health-care access almost certainly contribute too.

Reaching a Diagnosis

Diagnosing sarcoidosis in the eye is tricky because the inflammation looks similar to several other conditions. Tuberculosis, syphilis, certain viral infections, autoimmune conditions like Vogt-Koyanagi-Harada disease, and even lymphoma inside the eye can all produce overlapping findings.¹ Ruling those out is actually the first formal step in the diagnostic process.

The International Workshop on Ocular Sarcoidosis (IWOS) has published revised criteria to standardize how eye doctors approach the diagnosis. The framework relies on seven clinical signs seen inside the eye, eight systemic investigations (blood tests, imaging, and other workups), and three tiers of diagnostic certainty depending on whether a tissue biopsy has confirmed granulomas.⁷ In practice, this means a patient may receive a “definite,” “presumed,” or “probable” diagnosis based on how many clinical and laboratory criteria they meet, even without a biopsy.

Blood Tests and Biomarkers

Most people have heard of angiotensin-converting enzyme (ACE) as a blood test for sarcoidosis. ACE levels are elevated in some sarcoidosis patients, but the test is far from perfect when used for the eye form of the disease. In one study focusing on uveitis patients, serum ACE had a sensitivity of only about 44%, meaning it missed more than half of confirmed cases.⁸ Its specificity was excellent (no false positives in that study), but a test that catches fewer than half of true cases leaves a lot of patients undiagnosed.

A newer and increasingly favored marker is soluble interleukin-2 receptor (sIL-2R). A meta-analysis found that sIL-2R levels had pooled sensitivity and specificity near 88% and 87%, respectively, significantly outperforming ACE.⁹ A separate head-to-head comparison confirmed that sIL-2R had better overall diagnostic value than ACE for sarcoidosis-related uveitis, and combining sIL-2R with a chest X-ray pushed sensitivity above 90%.¹⁰ Where available, sIL-2R is increasingly used as a first-line blood test, though ACE and lysozyme are still commonly ordered as part of a broader workup.

Combining both markers catches more cases than either alone. In one study, about 75% of sarcoid uveitis patients had an elevated sIL-2R or ACE or both, compared to only 44% when ACE was checked by itself.⁸

Imaging and Biopsy

Diagnosis typically involves both looking at the eye in detail and checking the rest of the body for sarcoidosis. On the ophthalmic side, optical coherence tomography (OCT) can reveal macular swelling or subtle retinal changes, while fluorescein angiography highlights leaking blood vessels and areas of active inflammation.¹¹ These imaging techniques help the eye doctor grade severity and track how well treatment is working over time.

On the systemic side, a chest X-ray or CT scan is standard. The majority of sarcoidosis patients have swollen lymph nodes or other changes in the lungs, even when they feel perfectly fine from a breathing standpoint. That chest imaging does double duty: it supports the diagnosis and provides a target for biopsy if one is needed.¹²

When tissue confirmation is needed, a lung-based procedure using ultrasound-guided needle sampling of enlarged lymph nodes (called EBUS-TBNA) has become the go-to approach for many pulmonologists, with diagnostic yields above 90% in some comparisons.¹³ Sometimes eye doctors take a biopsy from the conjunctiva instead, which is less invasive but also less reliable. In one series, directed conjunctival biopsy found granulomas in about 43% of cases using standard processing, and a more thorough sectioning technique pushed that yield up to around 63%.¹⁴ So while a conjunctival biopsy can clinch the diagnosis when it comes back positive, a negative result does not rule sarcoidosis out.

First-Line Treatment with Corticosteroids

Steroid eye drops are the backbone of treatment for the front-of-the-eye inflammation that most patients experience first. Expert consensus recommends high-frequency dosing: for severe anterior uveitis, drops like prednisolone acetate are given at least ten times a day initially, tapering down as inflammation quiets. For moderate flares, at least six times a day is typical.¹⁵ A dilating drop (cycloplegic) is usually added to keep the pupil moving, which helps prevent the iris from scarring to the lens.

When inflammation is in the middle or back of the eye, topical drops cannot reach deeply enough. In those cases, oral corticosteroids (prednisone or prednisolone) are first-line, typically started at a dose based on body weight and maintained at the starting dose for two to four weeks before a gradual taper. Average total oral steroid courses run three to six months. Alternatively, a steroid can be injected near or inside the eye, and long-acting intravitreal corticosteroid implants are another option for localized disease.¹⁵ The challenge with steroids is that they come with real side effects: weight gain, bone thinning, elevated blood sugar, and in the eye specifically, cataracts and glaucoma. That is why the goal is always to control inflammation and then transition off steroids as quickly as it is safe to do so.

Steroid-Sparing Drugs and Biologics

Many patients with chronic or recurrent ocular sarcoidosis need a steroid-sparing agent to keep inflammation under control without the long-term fallout of corticosteroids. The expert-recommended first choices include methotrexate, mycophenolate mofetil, azathioprine, and cyclosporine.¹⁵ Of these, methotrexate is the most commonly used in practice, often given as a weekly low-dose oral tablet. Mycophenolate mofetil has shown effectiveness in controlling ocular sarcoidosis specifically, with a manageable side-effect profile and a documented ability to reduce the steroid dose patients need.¹⁶

When conventional immunosuppressants fail, biologic therapies that block tumor necrosis factor (TNF) enter the picture. These are injectable or infused drugs that target a specific inflammatory molecule central to granuloma formation. Infliximab and adalimumab are the two most widely studied. In sarcoidosis involving multiple organs, infliximab has the broadest track record, but adalimumab appears roughly equivalent in how well it works and has been found to be the most effective biologic for maintaining remission in chronic non-infectious uveitis in both adults and children. Etanercept, a different type of TNF blocker, has not proven useful in either sarcoidosis or uveitis and is generally avoided for these conditions.¹⁷ Biologic therapies are generally well tolerated, though they do carry an increased risk of infection and require screening for latent tuberculosis before starting.

Newer Therapies Under Investigation

For the subset of patients whose disease resists everything described above, several newer drug classes are being explored. Researchers are looking at agents that block interleukin-6 (an inflammatory signaling molecule), Janus kinase (JAK) inhibitors that interfere with broader immune signaling pathways, and mTOR inhibitors that affect immune cell growth and activation.¹⁸ These drugs are already approved for other inflammatory conditions, so their safety profiles are reasonably well characterized, but their use in ocular sarcoidosis is still being validated in controlled trials. The research reflects a broader shift toward more targeted, pathway-specific treatments rather than blunt immunosuppression.

What Drives Visual Outcomes

The prognosis for ocular sarcoidosis varies widely. Many patients preserve good vision with timely treatment, but some face progressive loss despite aggressive therapy. One study that looked at which factors predicted poor visual outcomes found that cystoid macular edema, the swelling in the central retina, was the strongest independent predictor of ending up with vision of 20/50 or worse. Other factors linked to worse outcomes in the initial analysis included iris nodules, cataract, and being older at diagnosis, though macular edema was the only one that held up when all variables were considered together.¹⁹

The practical implication is straightforward: controlling macular edema aggressively matters more than almost any other single treatment target. If your eye doctor mentions macular swelling on an OCT scan, that finding warrants prompt and sustained treatment. The good news is that prompt therapy can reverse visual damage in many cases, but delay is costly because once inflammation scars the retina, the damage becomes permanent.²

The Toll on Quality of Life

Vision loss from sarcoidosis does not exist in a vacuum. Patients with ocular involvement score significantly lower on vision-related quality-of-life measures compared to sarcoidosis patients whose eyes are spared.²⁰ That finding is intuitive, but the details are worth noting: patients with visual acuity of 20/100 or worse had the steepest drops in quality-of-life scores, and lower household income further compounded the problem, presumably because of reduced access to care and the financial burden of chronic treatment.

Separately, research has found that patients on systemic therapy (oral steroids or immunosuppressants) report lower quality-of-life scores regardless of their visual acuity, suggesting that the treatment burden itself weighs heavily.²¹ Frequent eye-drop schedules, blood-test monitoring for immunosuppressants, and the side effects of oral steroids all add up. This is one reason eye doctors try to move patients to the lowest effective maintenance regimen as quickly as possible, and why local treatments (injections, implants) are sometimes preferred over systemic drugs when the disease is limited to the eyes.

Ocular Sarcoidosis in Children

Children can develop ocular sarcoidosis too, though it tends to look somewhat different. In adults, the disease is most often either panuveitis (affecting all layers) or anterior uveitis, depending on the population studied. In children over five, granulomatous anterior uveitis is present in roughly a quarter to a third of cases, and at least one study has found that children are actually more likely to have non-granulomatous (less classic-looking) anterior inflammation than the typical granulomatous pattern seen in adults. In European pediatric populations, anterior-segment inflammation is the most frequent manifestation, while in multi-ethnic Asian populations, panuveitis dominates.²²

A related condition called Blau syndrome, a rare genetic form of granulomatous disease that begins in early childhood, has strikingly high rates of eye involvement. About three-quarters to four-fifths of children with Blau syndrome develop ocular disease, almost always bilateral, and the most common pattern is panuveitis.²² Because children are less likely to complain about mild visual symptoms, routine eye screening in any child diagnosed with sarcoidosis or Blau syndrome is important to catch inflammation before it damages structures that are still developing.

What Happens at the Immune Level

At the cellular level, the inflammation in ocular sarcoidosis is driven heavily by a particular branch of the immune system. Analysis of fluid from inside the eyes of affected patients shows elevated levels of T helper 1 (Th-1) cytokines, the signaling molecules that ramp up a specific arm of the immune response. These cytokines promote T cell activation and multiplication within the eye, sustaining the chronic inflammation that causes tissue damage over time.²³ Understanding this pathway is part of what has led researchers toward more targeted treatments. The biologics and newer drugs discussed earlier work precisely because they interrupt specific links in this inflammatory chain rather than suppressing the immune system broadly. As the molecular picture becomes clearer, the hope is that treatments will become more precise and carry fewer side effects, though that goal remains a work in progress.

1
The Journal of Rheumatology. Ocular Involvement in Sarcoidosis
2
PubMed Central. Management of chronic ocular sarcoidosis: challenges and solutions
3
PubMed Central. Ocular Sarcoidosis
4
Autoimmunity Reviews. Sarcoidosis and uveitis
5
PubMed. “Candle wax dripping” lesions in ocular sarcoidosis
6
Investigative Ophthalmology & Visual Science. Genetic Susceptibility to Ocular Sarcoidosis: A Comparative Analysis of Genome-Wide Association Studies
7
PubMed. Revised criteria of International Workshop on Ocular Sarcoidosis (IWOS) for the diagnosis of ocular sarcoidosis
8
PubMed Central. Usefulness of Combined Measurement of Serum Soluble IL-2R and Angiotensin-Converting Enzyme in the Detection of Uveitis Associated with Japanese Sarcoidosis
9
PubMed Central. Role of serum soluble interleukin-2 receptor level in the diagnosis of ocular and non-ocular sarcoidosis: a systematic review and meta-analysis
10
JAMA Ophthalmology. Diagnostic Value of Serum-Soluble Interleukin 2 Receptor Levels vs Angiotensin-Converting Enzyme in Patients With Sarcoidosis-Associated Uveitis
11
PubMed. Multimodal Imaging in Ocular Sarcoidosis
12
PubMed Central. Progress in the diagnosis of ocular sarcoidosis
13
PubMed Central. Definite Ocular Sarcoidosis Using Endobronchial Ultrasonography with Transbronchial Needle Aspiration
14
PubMed Central. Directed conjunctival biopsy and impact of histologic sectioning methodology on the diagnosis of ocular sarcoidosis
15
Investigative Ophthalmology & Visual Science. Expert recommendations for management of ocular sarcoidosis
16
Investigative Ophthalmology & Visual Science. Mycophenolate Mofetil in Ocular Sarcoidosis
17
PubMed Central. Biologic Therapies in Sarcoidosis and Uveitis: A Review
18
Current Opinion in Immunology. Ocular sarcoidosis: from clinical signs to targeted interventions
19
Investigative Ophthalmology & Visual Science. Risk Factors for Poor Visual Outcome in Patients With Ocular Sarcoidosis
20
PubMed Central. Quality of Life in Sarcoidosis: Comparing the Impact of Ocular and Non-ocular Involvement of the Disease
21
Investigative Ophthalmology & Visual Science. Health Related Quality of Life in Patients with Uveitis and Sarcoidosis
22
PubMed Central. Ocular sarcoidosis in adults and children: update on clinical manifestation and diagnosis
23
Investigative Ophthalmology & Visual Science. Simultaneous Analysis of Multiple Cytokines in the Vitreous of Patients with Sarcoid Uveitis